Core Insights - Fennec Pharmaceuticals announced the grant of incentive stock options to 24 new non-executive employees as part of its 2026 Equity Inducement Plan, totaling 377,500 shares [1][2] Group 1: Stock Options and Inducement Plan - The incentive stock options (ISOs) have an exercise price of $5.77 per share, equal to the closing price on March 30, 2026, and a term of ten years from the grant date [3] - One-third of the shares underlying each ISO will vest on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the following 24 months, contingent on continued employment [3] Group 2: Company Overview - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, with its primary product being PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity [4] - PEDMARK received FDA approval in September 2022, followed by European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI [4] - In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand, with the product already available in the U.K. and Germany [5]

Core Viewpoint - Aquestive Therapeutics, Inc. announced an inducement grant for Dr. Matthew Greenhawt, Chief Medical Officer, under its 2022 Equity Inducement Plan, approved by the Compensation Committee [1][2]. Group 1: Inducement Grant Details - Dr. Greenhawt will receive 75,000 Restricted Stock Units (RSUs) and 50,000 non-qualified common stock options, with grants scheduled for March 9, 2026 [2]. - The RSUs and Options will vest 25% after the first and second anniversaries of the grant date, and 50% on the third anniversary, contingent on continued employment [2]. - The Options will have a ten-year term with an exercise price equal to the closing price of the common stock on the grant date [2]. Group 2: Company Overview - Aquestive is a pharmaceutical company focused on innovative science and delivery technologies to improve patients' lives [3]. - The company is a leader in delivering medications via oral film and operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [3]. - It manufactures four commercialized products for licensees globally and has a library of over 20 epinephrine prodrugs for allergy and dermatological indications [3].

Core Points - Lifecore Biomedical, Inc. has granted a restricted stock unit (RSU) award for 15,000 shares and stock options for 30,000 shares to a newly hired employee as part of its Equity Inducement Plan [1][2] - The RSUs will vest on the third anniversary of the grant date, while the stock options will vest one-third on the first anniversary and the remaining shares monthly thereafter, subject to continued employment [3] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and partners with global and emerging biopharmaceutical and biotechnology companies [4]

Company Overview - Sutro Biopharma, Inc. is focused on the discovery and development of precisely designed cancer therapeutics, particularly antibody drug conjugates (ADCs) [7] - The company is advancing a robust early-stage pipeline of novel exatecan-based and dual-payload ADCs, supported by high-value collaborations and industry partnerships [7] Leadership Appointment - Greg Chow has been appointed as Chief Financial Officer (CFO) effective June 2, 2025, bringing over 25 years of executive leadership experience in corporate finance, capital markets, and drug development operations [1][2] - Chow's previous roles include Chief Financial and Business Officer at NodThera, CFO at Freenome Holdings, and CFO at Frontier Medicines, where he successfully executed significant financing rounds [2][3] Financial Strategy and Goals - The leadership of Greg Chow is expected to enhance financial discipline, operational efficiency, and capital strategy, positioning the company to achieve key clinical milestones [2] - Chow expressed enthusiasm about joining Sutro, highlighting the company's unique position in ADC innovation and its powerful cell-free technology platform for drug discovery [2] Inducement Grants - Sutro has granted Greg Chow a restricted stock unit award for 100,000 shares and a non-qualified option to purchase 275,000 shares under the 2021 Equity Inducement Plan [4][5] - The option will have an exercise price equal to the closing price of Sutro's common stock on the appointment date, with vesting schedules for both the restricted stock and option awards [6]